Dihydromyricetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma.

MLA

Zhao, Zhiqiang, et al. “Dihydromyricetin Activates AMP-Activated Protein Kinase and P38(MAPK) Exerting Antitumor Potential in Osteosarcoma.” Cancer Prevention Research (Philadelphia, Pa.), vol. 7, no. 9, Sept. 2014, pp. 927–38. EBSCOhost, https://doi.org/10.1158/1940-6207.CAPR-14-0067.

APA

Zhao, Z., Yin, J., Wu, M., Song, G., Xie, X., Zou, C., Tang, Q., Wu, Y., Lu, J., Wang, Y., Wang, J., Kang, T., Jia, Q., & Shen, J. (2014). Dihydromyricetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma. Cancer Prevention Research (Philadelphia, Pa.), 7(9), 927–938. https://doi.org/10.1158/1940-6207.CAPR-14-0067

Chicago

Zhao, Zhiqiang, Jun-qiang Yin, Man-si Wu, Guohui Song, Xian-biao Xie, Changye Zou, Qinglian Tang, et al. 2014. “Dihydromyricetin Activates AMP-Activated Protein Kinase and P38(MAPK) Exerting Antitumor Potential in Osteosarcoma.” Cancer Prevention Research (Philadelphia, Pa.) 7 (9): 927–38. doi:10.1158/1940-6207.CAPR-14-0067.